 | • レポートコード：C-MOR-100260 • 出版社/出版日：Mordor Intelligence / 2019年9月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Multi User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site License | ￥888,000 (USD6,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、がん免疫治療の世界市場について調査・分析し、がん免疫治療の世界市場規模、市場動向、市場環境分析、市場展望、セグメント別分析、地域別分析、関連企業情報など以下の構成でお届け致します。 |
Market Overview
Cancer Immunotherapy Market is expected to witness a CAGR of 12.2% during the forecast period. Certain factors that are driving the market are R&D activities, increasing effectivity and accuracy of newer therapies, growing prevalence of cancer.
The incidence of cancer is increasing significantly and has been the major factor for the growth of the cancer immunotherapy market. Cancer damages the immune system, as cancer cells produce the self-antigen. The cancer immunotherapy plays a vital role in the maintenance of the immune system, and it targets the infectious agents that may cause cancer through the production of the antibodies. Cancer Immunotherapy is considered as new therapy and is not popular compared to the other alternative therapeutic drugs. However, cancer immunotherapy has shown great potential over the past few years. Also, with healthcare physicians looking for the alternative therapies due to the huge burden of cancer cases and side effects of the present therapies, the market of cancer immunotherapy is expected to grow with a high growth rate during the forecast period.
However, in the expanding market for medical therapies, there are stringent regulatory policies in place to ensure the safety of therapies. The FDA review process takes twice as much as time as European regulatory commissions’ review bodies. The presence of stringent regulations is dampening the innovation in the market and hindering the growth of this market.
Scope of the Report
Immunotherapy is a treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. This can be done either by stimulating one’s own immune system to work harder and smarter to attack cancer cells, or by giving one immune system components, such as man-made immune system proteins.
Key Market Trends
Cancer Vaccines are Expected to Show Lucrative Growth Opportunity in the Therapy Type Segment
Various advancements are taking place in the field of cancer vaccines owing to the ongoing research studies all across the globe. Cancer vaccines can majorly be classified into two types i.e. preventive vaccines and therapeutic vaccines. Preventive cancer vaccine or prophylactic vaccines are the vaccines that are intended to prevent the development of cancer in healthy people. These vaccines work by preventing infectious agents that cause or contribute to the development of cancer. These vaccines are similar to a traditional vaccine that helps in preventing infectious diseases, such as polio and measles, by protecting the body against infections. Most of the preventive vaccines stimulate the production of antibodies, which bind to the specifically targeted microbes and block their ability to cause infection.
North America Dominates the Market and Expected to do Same in the Forecasted Period
This is due to the high prevalence of cancer, along with developed healthcare infrastructure in the region. According to the National Cancer Institute, preventive cancer vaccines were approved to treat cancers caused by the use of vaccines, namely Human papillomavirus (HPV) vaccines and the Hepatitis B virus (HBV). However, there are many other immunotherapies that were approved by the FDA for the prevention of cancer. In April 2010, the first cancer treatment vaccine, called sipuleucel-T (Provenge), was approved by the FDA. This vaccine was approved for use in men with metastatic prostate cancer. It was designed to stimulate an immune response to prostatic acid phosphatase (PAP), which is an antigen found in most prostate cancer cells. Moreover, in October 2015, the first oncolytic virus therapy, called talimogene laherparepvec (T-VEC, or Imlygic), was also approved by the FDA. This vaccine is used for the treatment of metastatic melanoma that cannot be surgically removed.
Competitive Landscape
The Cancer Immunotherapy market is highly competitive and consists of a few major players. Companies like Amgen Inc., Astellas Pharma, Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffman La Roche, Merck and Co., Novartis, OSE Immunotherapeutics, among others, hold the substantial market share in the Cancer Immunotherapy market.
Reasons to Purchase this report:
The market estimate (ME) sheet in Excel format
Report customization as per the client’s requirements
3 months of analyst support
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising R&D Activities
4.2.2 Increasing Effectivity and Accuracy of Newer Therapies
4.2.3 Growing Prevalence of Cancer
4.3 Market Restraints
4.3.1 High Cost Coupled with Expensive Development
4.3.2 Stringent Regulatory Factors
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Therapy Type
5.1.1 Monoclonal Antibodies
5.1.2 Cancer Vaccines
5.1.3 Immunomodulators
5.1.4 Immune Check Point Inhibitors
5.1.5 Others
5.2 Application
5.2.1 Prostate Cancer
5.2.2 Breast Cancer
5.2.3 Skin Cancer
5.2.4 Lung Cancer
5.2.5 Others (Pancreatic, Colorectal, Ovarian, etc.)
5.3 End Users
5.3.1 Hospitals and Clinics
5.3.2 Cancer Research Centers
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 Astellas Pharma, Inc.
6.1.3 AstraZeneca
6.1.4 Bayer AG
6.1.5 Bristol-Myers Squibb
6.1.6 Eli Lilly and Co.
6.1.7 F. Hoffman La Roche
6.1.8 Merck and Co.
6.1.9 Novartis
6.1.10 OSE Immunotherapeutics
7 MARKET OPPORTUNITIES AND FUTURE TRENDS